Lower concentrations of thrombin-antithrombin complex (TAT) correlate to higher recanalisation rates among ischaemic stroke patients treated with t-PA

Thrombosis and Haemostasis

Volumn 102, Issue 4, 2009, Pages 759-764

  Fernandez Cadenas, Israel ^a   Mendioroz, Maite ^a   Munuera, Josep ^a   Alvarez Sabin, José ^a   Rovira, Alex ^a   Quiroga, Adoracion ^a   Corbeto, Natalia ^a   Rubiera, Marta ^a   Delgado, Pilar ^a   Rosell, Anna ^a   Ribó, Marc ^a   Molina, Carlos A ^a   Montaner, Joan ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

Argatroban; Plasmin; t PA; Thrombin; Thrombolysis

Indexed keywords

THROMBIN ANTITHROMBIN COMPLEX; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; AGED; ARTICLE; CEREBROVASCULAR ACCIDENT; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DOPPLER ECHOGRAPHY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE CEREBRAL ARTERY OCCLUSION; MORTALITY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RECANALIZATION; REVASCULARIZATION; RISK FACTOR;

AGED; AGED, 80 AND OVER; ANTITHROMBIN III; BIOLOGICAL MARKERS; BRAIN ISCHEMIA; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; INFARCTION, MIDDLE CEREBRAL ARTERY; MALE; MIDDLE AGED; PEPTIDE HYDROLASES; PROGNOSIS; PROTEIN BINDING; RISK FACTORS; STROKE; THROMBIN; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME; ULTRASONOGRAPHY, DOPPLER, TRANSCRANIAL;

EID: 70449478957     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH08-06-0398     Document Type: Article

References (37)

1. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995; 333: 1581-1587.
2. Wahlgren N, Ahmed N, Davalos A, et al. SITSMOST investigators. Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITSMOST): an observational study. Lancet 2007; 369: 275-282.
3. Alexandrov AV, Demchuk AM, Felberg RA, et al. High rate of complete recanalization and dramatic clinical recovery during tPA infusion when continuous monitored with 2-MHz transcranial Doppler monitoring. Stroke 2000; 31: 610-614.
4. Molina CA, Montaner J, Abilleira S, et al. Time course of tissue plasminogen activator-induced recanalization in acute cardioembolic stroke: a case-control study. Stroke 2001; 32: 2821-2827. (Pubitemid 33134472)
5. Ribo M, Montaner J, Molina CA, et al. Admission fibrinolytic profile is associated with symptomatic hemorrhagic transformation in stroke patients treated with tissue plasminogen activator. Stroke 2004; 35: 2123-2127. (Pubitemid 39129572)
6. Ribo M, Montaner J, Molina CA, et al. Admission fibrinolytic profile predicts clot lysis resistance in stroke patients treated with tissue plasminogen activator. Thromb Haemost 2004; 91: 1146-1151. (Pubitemid 38821271)
7. Fernandez-Cadenas I, Molina CA, Alvarez-Sabin J, et al. ACE gene polymorphisms influence t-PA-induced brain vessel reopening following ischemic stroke. Neurosci Lett 2006; 398: 167-171.
8. Gonzalez-Conejero R, Fernandez-Cadenas I, Iniesta JA, et al. Proyecto Ictus Research Group Role of fibrinogen levels and factor XIII V34L polymorphism in thrombolytic therapy in stroke patients. Stroke 2006; 37: 2288-2293. (Pubitemid 44337171)
9. Rosell A, Alvarez-Sabin J, Arenillas JF, et al. A matrix metalloproteinase protein array reveals a strong relation between MMP-9 and MMP-13 with diffusion-weighted image lesion increase in human stroke. Stroke 2005; 36: 1415-1420. (Pubitemid 40967504)
10. Montaner J, Molina CA, Monasterio J, et al. Matrix metalloproteinase-9 pretreatment level predicts intracranial hemorrhagic complications after thrombolysis in human stroke. Circulation 2003; 107: 598-603. (Pubitemid 36176811)
11. Castellanos M, Leira R, Serena J, et al. Plasma cellular- fibronectin concentration predicts hemorrhagic transformation after thrombolytic therapy in acute ischemic stroke. Stroke 2004; 35: 1671-1676 (Pubitemid 38823645)
12. Davie EW, Kulman JD. An overview of the structure and function of thrombin. Semin Thromb Hemost 2006; 32.
13. Yang DT, Flanders MM, Kim H, et al. Elevated factor XI activity levels are associated with an increased odds ratio for cerebrovascular events. Am J Clin Pathol 2006; 126: 411-415. (Pubitemid 44338794)
14. Salomon O, Steinberg DM, Koren-Morag N, et al. Reduced incidence of ischemic stroke in patients with severe factor XI deficiency. Blood 2008; 111: 4113-4117.
15. Santamaría A, Martínez-Rubio A, Mateo J, et al. Homozygosity of the T allele of the 46 C-->T polymorphism in the F12 gene is a risk factor for acute coronary artery disease in the Spanish population. Haematologica 2004; 89: 878-879. (Pubitemid 38981357)
16. Fernandez-Cadenas I, Alvarez-Sabin J, Ribo M, et al. Influence of thrombin-activatable fibrinolysis inhibitor and plasminogen activator inhibitor-1 gene polymorphisms on tissue-type plasminogen activator-induced recanalization in ischemic stroke patients. J Thromb Haemost 2007; 5: 1862-1868. (Pubitemid 47288943)
17. Tanne D, Macko RF, Lin Y, et al. NINDS rtPA Stroke Study Group. Hemostatic activation and outcome after recombinant tissue plasminogen activator therapy for acute ischemic stroke. Stroke 2006; 37: 1798-1804.
18. Rha JH, Saver JL. The impact of recanalization on ischemic stroke outcome: a meta-analysis. Stroke 2007; 38: 967-973. (Pubitemid 46568460)
19. Adams HP, Bendixen BH, Kappelle LJ, et al. 3rd. Classification of subtype of acute ischemic stroke: definitions for use in a multicenter clinical trial. Stroke 1993; 24: 35-41.
20. Brott TG, Haley EC, Levy DE, et al. Urgent therapy for stroke, part I: pilot study of tissue plasminogen activator administered within 90 minutes. Stroke 1992; 23: 632-640.
21. Demchuk AM, Burgin WS, Christou I, et al. Thrombolysis in Brain Ischemia (TIBI) transcranial Doppler flow grades predict clinical severity, early recovery, and mortality in patients treated with intravenous tissue plasminogen activator. Stroke 2001; 32: 89-93. (Pubitemid 32063829)
22. Burgin WS, Malkoff M, Demchuk AM, et al. Transcranial Doppler ultrasound criteria for recanalization after thrombolysis for middle cerebral artery stroke. Stroke 2000; 31: 1128-1132. (Pubitemid 30253536)
23. Ribo M, Molina CA, Rovira A, et al. Safety and efficacy of intravenous tissue plasminogen activator stroke treatment in the 3- to 6-hour window using multimodal transcranial Doppler/MRI selection protocol. Stroke 2005; 36: 602-606. (Pubitemid 40344163)
24. Pessin M, del Zoppo G, Estol C. Thrombolytic agents in the treatment of stroke. Clin Neuropharmacol 1990; 13: 271-289.
25. Clark RA, Watanabe AT, Bradley WG, et al. Acute hematomas: effects of deoxygenation, hematocrit, and fibrin-clot formation and retraction on T2 shortening. Radiology 1990; 175: 201-206.
26. Atlas SW, Mark AS, Grossman RI, et al. Intracranial hemorrhage: gradient-echo MRI imaging at 1.5T - comparison with spin-echo imaging and clinical applications. Radiology 1988; 168: 803-807.
27. Hayman LA, Ford JJ, Taber KH, et al. T2 effect of hemoglobin concentration: assessment with in vitro MR spectroscopy. Radiology 1988; 168: 489-491. (Pubitemid 18185128)
28. Hayman LA, Taber KH, Ford JJ, et al. Effect of clot formation and retraction on spin-echo MR images of blood: an in vitro study. AJNR Am J Neuroradiol 1989; 10: 1155-1158.
29. Gulba DC, Barthels M, Westhoff-Bleck M, et al. Increased thrombin levels during thrombolytic therapy in acute myocardial infarction: relevance for the success of therapy. Circulation 1991; 83: 937-944.
30. Scharfstein JS, Abendschein DR, Eisenberg PR, et al. for the TIMI-5 Investigators. Usefulness of fibrinogenolytic and procoagulant markers during thrombolytic therapy in predicting clinical outcomes in acute myocardial infarction: Thrombolysis in Myocardial Infarction. Am JCardiol 1996; 78: 503-510.
31. Ray KK, Morrow DA, Gibson CM, et al. for the ENTIRE-TIMI 23 Study Group. Predictors of the rise in vWF after ST elevation myocardial infarction: implications for treatment strategies and clinical outcome: an ENTIRE-TIMI 23 Substudy. Eur Heart J 2005; 26: 440-446.
32. Yamada K, Tsuji J, Kimura S, et al. Effects of argatroban and heparin on thrombus formation and tissue plasminogen activator-induced thrombolysis in a microvascular thrombosis model. Thromb Res 2003; 109: 55-64. (Pubitemid 36385048)
33. Morris DC, Zhang L, Zheng GZ, et al. Extension of the therapeutic window for recombinant tissue plasminogen activator with argatroban in a rat model of embolic stroke. Stroke 2001; 32: 2635-2640. (Pubitemid 33055318)
34. Kobayashi S, Tazaki Y. Effect of the thrombin inhibitor argatroban in acute cerebral thrombosis. Semin Thromb Haemost 1997; 23: 531-534. (Pubitemid 28114049)
35. Hosomi N, Naya T, Kohno M, et al. The Japan Standard Stroke Registry Study Group. Efficacy of anti-coagulant treatment with argatroban on cardioembolic stroke. J Neurol 2007; 254: 605-612
36. LaMonte MP, Marshall LN, Wang DZ, et al. ARGIS-1 Investigators. Argatroban anticoagulation in patients with acute ischemic stroke. Stroke 2004; 35: 1677-1682.
37. Sugg RM, Pary JK, Uchino K, et al. Argatroban tPA stroke study: study design and results in the first treated cohort. Arch Neurol 2006; 63: 1057-1062. (Pubitemid 44232309)